In April 2025, BRIC-InStem in Bengaluru collaborated with which medical institution to successfully conduct India’s first gene therapy trial for Haemophilia?
Christian Medical College, Vellore
India’s first human gene therapy trial for haemophilia was carried out by BRIC-InStem (Institute for Stem Cell Science and Regenerative Medicine), Bengaluru, in collaboration with Christian Medical College (CMC), Vellore.
The trial used a lentiviral vector to insert a working copy of the clotting-factor gene into the patient’s own stem cells, so the body could produce the missing clotting factor and prevent bleeding episodes in Haemophilia A.
The results were published in the New England Journal of Medicine, marking a landmark for indigenous gene-therapy research in India.
Hence, BRIC-InStem partnered with Christian Medical College, Vellore.
Similar Questions
Which international health day was celebrated on November 14, 2025?
What is the name of India's first indigenous CRISPR-based gene therapy for Sickle Cell Disease, launched in November 2025?
What was the theme for World Leprosy Day 2025?
Under an MoU signed on 2 September 2025 between the Department of Ex-Servicemen Welfare and Patanjali Yoggram, nearly six million veterans and their dependents will receive free access to which type of treatment?
Important Questions from Health
Who led the team that explored innovative approaches to combat Alzheimer’s disease at the Bose Institute?
Which parasitic disease has Niger officially eliminated as a public health threat?
Which country has initiated the first-ever clinical trial for a vaccine targeting the Sudan species of the Ebola virus?
Consider the following statements:
Statement-I- Biolumpivaxin vaccine is expected to provide long-lasting immunity against all strains of the Lumpy Skin Disease virus.
Statement-II- Vaccines typically stimulate the immune system to produce antibodies that can neutralize the specific pathogen they are designed to target
Which one of the following is correct in respect to the above statements?
Consider the following statements:
Statement-I- Biolumpivaxin vaccine is expected to provide long-lasting immunity against all strains of the Lumpy Skin Disease virus.
Statement-II- Vaccines typically stimulate the immune system to produce antibodies that can neutralize the specific pathogen they are designed to target
Which one of the following is correct in respect to the above statements?
